Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario A Eisenberger

Showing results (1-10 of 155) with videos related to

Pageof 16
Sort By:
Seminars in Urologic Oncology|August 29, 2002
Therapeutic considerations for patients with high-risk, nonmetastatic, prostate cancerMario A Eisenberger
Urologic Oncology|July 3, 2008
Evolving new treatments for patients with prostate cancer: the advanced disease paradigm of the PSA eraMario A Eisenberger
European Urology|January 6, 2010
Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reide AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper C, Kaye S, Dearnaley D, Lee G, de Bono JS. J Clin Oncol 2008;26:4563-71Mario A Eisenberger
Reviews in Urology|September 21, 2006
A multi-institutional pilot study of adjuvant docetaxel for patients with prostate cancer at high risk for relapse after radical prostatectomyMario A Eisenberger
Reviews in Urology|September 21, 2006
A multi-institutional pilot study of adjuvant docetaxel for patients with prostate cancer at high risk for relapse after radical prostatectomyMario A Eisenberger
European Urology|October 14, 2008
Treat early or wait? A stubborn question that remains unansweredMario A Eisenberger
Oncology (Williston Park, N.Y.)|July 25, 2009
LHRH antagonists vs LHRH agonists: which is more beneficial in prostate cancer therapy?Daniel Keizman, Mario A Eisenberger
Nature Clinical Practice. Urology|July 31, 2008
Does short-term ADT before and during radiation therapy improve outcomes in locally advanced prostate cancer?Emmanuel S Antonarakis, Mario A Eisenberger
Nature Clinical Practice. Oncology|October 30, 2008
Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?Emmanuel S Antonarakis, Mario A Eisenberger
European Urology|April 9, 2016
A Potential Predictive Role for Prostate-specific Antigen Changes at 4 Weeks?Benjamin L Maughan, Mario A Eisenberger
Pageof 16

Showing results (1-10 of 155) with videos related to

Sort By:
Pageof 16
Seminars in Urologic Oncology|August 29, 2002
Therapeutic considerations for patients with high-risk, nonmetastatic, prostate cancerMario A Eisenberger
Urologic Oncology|July 3, 2008
Evolving new treatments for patients with prostate cancer: the advanced disease paradigm of the PSA eraMario A Eisenberger
European Urology|January 6, 2010
Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reide AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper C, Kaye S, Dearnaley D, Lee G, de Bono JS. J Clin Oncol 2008;26:4563-71Mario A Eisenberger
Reviews in Urology|September 21, 2006
A multi-institutional pilot study of adjuvant docetaxel for patients with prostate cancer at high risk for relapse after radical prostatectomyMario A Eisenberger
Reviews in Urology|September 21, 2006
A multi-institutional pilot study of adjuvant docetaxel for patients with prostate cancer at high risk for relapse after radical prostatectomyMario A Eisenberger
European Urology|October 14, 2008
Treat early or wait? A stubborn question that remains unansweredMario A Eisenberger
Oncology (Williston Park, N.Y.)|July 25, 2009
LHRH antagonists vs LHRH agonists: which is more beneficial in prostate cancer therapy?Daniel Keizman, Mario A Eisenberger
Nature Clinical Practice. Urology|July 31, 2008
Does short-term ADT before and during radiation therapy improve outcomes in locally advanced prostate cancer?Emmanuel S Antonarakis, Mario A Eisenberger
Nature Clinical Practice. Oncology|October 30, 2008
Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?Emmanuel S Antonarakis, Mario A Eisenberger
European Urology|April 9, 2016
A Potential Predictive Role for Prostate-specific Antigen Changes at 4 Weeks?Benjamin L Maughan, Mario A Eisenberger
Pageof 16